Contextualizing Clinical Success of Enhertu Combination to Secure First Line Approval in HER2+ Metastatic Breast Cancer - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Contextualizing Clinical Success of Enhertu Combination to Secure First Line Approval in HER2+ Metastatic Breast Cancer

2:30 pm - Tuesday 13th October 2026

Envisioning potential for Enhertu to move from advanced to early oncology settings
Delving into the clinical data and first-line approval of Enhertu combination therapy in HER2+ metastatic breast cancer
Laying out rationale driven research to identify combination partners complimentary to Enhertu mechanism

Speakers:

Ronald Fleming

Ronald Fleming

Executive Director, Clinical Development

Daiichi Sankyo